NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis → RSVP: Charles Payne’s Cash Flow Workshop (From Unstoppable Prosperity) (Ad) Free CPRX Stock Alerts $15.64 -0.01 (-0.06%) (As of 11:46 AM ET) Add Compare Share Share Today's Range$15.64▼$16.3350-Day Range$14.68▼$17.0152-Week Range$11.09▼$17.51Volume552,228 shsAverage Volume1.42 million shsMarket Capitalization$1.85 billionP/E Ratio25.64Dividend YieldN/APrice Target$26.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Catalyst Pharmaceuticals alerts: Email Address Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside64.6% Upside$26.71 Price TargetShort InterestBearish7.59% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.34Based on 11 Articles This WeekInsider TradingSelling Shares$803,000 Sold Last QuarterProj. Earnings Growth21.55%From $1.81 to $2.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.98 out of 5 starsMedical Sector14th out of 915 stocksPharmaceutical Preparations Industry5th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.59% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 22.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 1.9 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Catalyst Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $803,000.00 in company stock.Percentage Held by Insiders11.00% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 21.55% in the coming year, from $1.81 to $2.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 26.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 26.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 189.03.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 0.81. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchDo This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).Find out how you can too in this free video. About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesApril 11, 2024 | insidertrades.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney Sells 25,000 SharesMay 8, 2024 | msn.comCPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 10, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 8, 2024 | sfgate.comCatalyst: Q1 Earnings SnapshotMay 8, 2024 | msn.comCatalyst Pharmaceuticals Non-GAAP EPS of $0.38 beats by $0.08, revenue of $98.44M misses by $0.33MMay 8, 2024 | globenewswire.comCatalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | americanbankingnews.comCatalyst Pharmaceuticals (CPRX) Set to Announce Earnings on WednesdayMay 1, 2024 | finance.yahoo.comCatalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024May 10, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 25, 2024 | globenewswire.comSanthera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in MayApril 24, 2024 | investorplace.comDirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026April 23, 2024 | barrons.comCatalyst Pharmaceuticals Inc.April 22, 2024 | globenewswire.comCatalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024April 8, 2024 | msn.comSingle Catalyst Paves the Way for Efficient Drug SynthesisApril 7, 2024 | cnn.comCatalyst Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comCatalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)April 5, 2024 | nasdaq.comFirst Week of May 17th Options Trading For Catalyst Pharmaceuticals (CPRX)March 28, 2024 | finance.yahoo.comInsider Sell: Chief Compliance/Legal Officer Brian Elsbernd Sells 25,000 Shares of Catalyst ...March 28, 2024 | globenewswire.comCatalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayMarch 27, 2024 | markets.businessinsider.comDecoding 7 Analyst Evaluations For Catalyst PharmaceuticalsMarch 27, 2024 | globenewswire.comCatalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumMarch 27, 2024 | investorplace.com3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch ListMarch 22, 2024 | finance.yahoo.comInvestors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three yearsMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 15, 2024 | finance.yahoo.comCPRX Apr 2024 12.500 callMarch 15, 2024 | finance.yahoo.comCPRX Apr 2024 17.500 putMarch 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)See More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/10/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees167Year Founded2002Price Target and Rating Average Stock Price Target$26.43 High Stock Price Target$34.00 Low Stock Price Target$23.00 Potential Upside/Downside+68.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.61 Trailing P/E Ratio25.66 Forward P/E Ratio8.65 P/E Growth0.81Net Income$71.41 million Net Margins17.93% Pretax Margin23.73% Return on Equity26.56% Return on Assets22.13% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.68 Sales & Book Value Annual Sales$398.20 million Price / Sales4.64 Cash Flow$2.19 per share Price / Cash Flow7.16 Book Value$3.30 per share Price / Book4.74Miscellaneous Outstanding Shares118,011,000Free Float105,030,000Market Cap$1.85 billion OptionableOptionable Beta0.89 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Richard John Daly M.B.A. (Age 63)President, CEO & Director Comp: $68.12kDr. Steven R. Miller Ph.D. (Age 62)Executive VP, COO & Chief Scientific Officer Comp: $884.7kDr. Gary Ingenito M.D. (Age 68)Ph.D., Chief Medical & Regulatory Officer Comp: $811.39kMr. Jeffrey Del Carmen (Age 53)Executive VP & Chief Commercial Officer Comp: $799.82kMr. Michael W. Kalb CPA (Age 53)Executive VP, Treasurer & CFO Ms. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 60)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 48)Chief Strategy Officer Comp: $511.25kMore ExecutivesKey CompetitorsHarmony BiosciencesNASDAQ:HRMYEvotecNASDAQ:EVOStructure TherapeuticsNASDAQ:GPCRSchrödingerNASDAQ:SDGRSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsJupiter Asset Management Ltd.Sold 34,571 shares on 5/10/2024Ownership: 0.686%State Board of Administration of Florida Retirement SystemSold 7,800 shares on 5/9/2024Ownership: 0.018%US Bancorp DESold 16,690 shares on 5/8/2024Ownership: 0.041%ProShare Advisors LLCBought 3,614 shares on 5/8/2024Ownership: 0.019%Headlands Technologies LLCBought 9,675 shares on 5/8/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price target for 2024? 5 equities research analysts have issued twelve-month target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price targets range from $23.00 to $34.00. On average, they predict the company's share price to reach $26.71 in the next year. This suggests a possible upside of 64.6% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2024? Catalyst Pharmaceuticals' stock was trading at $16.81 at the beginning of the year. Since then, CPRX shares have decreased by 3.5% and is now trading at $16.23. View the best growth stocks for 2024 here. Are investors shorting Catalyst Pharmaceuticals? Catalyst Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 7,710,000 shares, an increase of 23.0% from the April 15th total of 6,270,000 shares. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is presently 5.9 days. Approximately 7.6% of the shares of the company are sold short. View Catalyst Pharmaceuticals' Short Interest. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.04. The biopharmaceutical company had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 26.56% and a net margin of 17.93%. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 GARP ETF (GRPZ), ALPS Medical Breakthroughs ETF (SBIO) and ERShares NextGen Entrepreneurs ETF (ERSX). What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $460.5 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include LSV Asset Management (0.76%), Jupiter Asset Management Ltd. (0.69%), Mesirow Institutional Investment Management Inc. (0.61%), Principal Financial Group Inc. (0.55%), Raymond James Financial Services Advisors Inc. (0.22%) and Russell Investments Group Ltd. (0.20%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CPRX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
